Skip to main content
Top
Published in: BMC Nephrology 1/2006

Open Access 01-12-2006 | Case report

Posttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case report

Authors: Roland Schmitt, Ute Kettritz, Friedrich C Luft, Ralph Kettritz

Published in: BMC Nephrology | Issue 1/2006

Login to get access

Abstract

Backround

Advancements in immunosuppressive therapy have significantly improved patient and graft survival following renal transplantation. This is paralleled by an increasing occurrence of posttransplantation malignancy.

Case presentation

We report on a patient who presented with a history reminding of colon cancer seven years after receiving a kidney transplant. Initial diagnostic imaging seemed to confirm this diagnosis showing a constricting colonic lesion. To our surprise, colonoscopy findings were unremarkable. Review of the imaging studies revealed that the tumor-like picture was caused by the renal graft impressing the intestine. The following search for malignancy in other locations resulted in the diagnosis of glioblastoma multiforme of which the patient died several weeks later.

Conclusion

Follow-up of renal transplant patients must include screening tests directed at tumor detection. Imaging studies and other tests in this patient group should be interpreted by physicians who are familiar with transplant related peculiarities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol. 2004, 15 (6): 1582-8. 10.1097/01.ASN.0000126194.77004.9B.CrossRefPubMed Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol. 2004, 15 (6): 1582-8. 10.1097/01.ASN.0000126194.77004.9B.CrossRefPubMed
2.
go back to reference London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP: Risk of neoplasia in renal transplant patients. Lancet. 346 (8972): 403-6. 10.1016/S0140-6736(95)92780-8. 1995, Aug 12 London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP: Risk of neoplasia in renal transplant patients. Lancet. 346 (8972): 403-6. 10.1016/S0140-6736(95)92780-8. 1995, Aug 12
3.
go back to reference Sheil AG, Disney AP, Mathew TH, Amiss N: De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc. 1993, 25 (1 Pt 2): 1383-4.PubMed Sheil AG, Disney AP, Mathew TH, Amiss N: De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc. 1993, 25 (1 Pt 2): 1383-4.PubMed
4.
go back to reference Seaman WE, Sleisenger M, Eriksson E, Koo GC: Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 138 (12): 4539-44. 1987 Jun 15 Seaman WE, Sleisenger M, Eriksson E, Koo GC: Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 138 (12): 4539-44. 1987 Jun 15
5.
go back to reference Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 351 (9103): 623-8. 10.1016/S0140-6736(97)08496-1. 1998 Feb 28 Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 351 (9103): 623-8. 10.1016/S0140-6736(97)08496-1. 1998 Feb 28
6.
go back to reference Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397 (6719): 530-4. 10.1038/17401. 1999 Feb 11 Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397 (6719): 530-4. 10.1038/17401. 1999 Feb 11
7.
go back to reference Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M: Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 76 (3): 597-602. 2003 Aug 15 Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M: Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 76 (3): 597-602. 2003 Aug 15
8.
go back to reference O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P: Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 309 (5742): 1871-4. 10.1126/science.1114233. 2005 Sep 16 O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P: Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 309 (5742): 1871-4. 10.1126/science.1114233. 2005 Sep 16
9.
go back to reference Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003, 63 (3): 917-26. 10.1046/j.1523-1755.2003.00805.x.CrossRefPubMed Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003, 63 (3): 917-26. 10.1046/j.1523-1755.2003.00805.x.CrossRefPubMed
10.
go back to reference Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002, 8 (2): 128-35. 10.1038/nm0202-128.CrossRefPubMed Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002, 8 (2): 128-35. 10.1038/nm0202-128.CrossRefPubMed
11.
go back to reference Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 80 (7): 883-9. 10.1097/01.TP.0000184006.43152.8D. 2005 Oct 15 Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 80 (7): 883-9. 10.1097/01.TP.0000184006.43152.8D. 2005 Oct 15
12.
go back to reference Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 352 (13): 1317-23. 10.1056/NEJMoa042831. 2005 Mar 31 Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 352 (13): 1317-23. 10.1056/NEJMoa042831. 2005 Mar 31
13.
go back to reference Ponticelli C, Passerini P: Gastrointestinal complications in renal transplant recipients. Transpl Int. 2005, 18 (6): 643-50. 10.1111/j.1432-2277.2005.00134.x.CrossRefPubMed Ponticelli C, Passerini P: Gastrointestinal complications in renal transplant recipients. Transpl Int. 2005, 18 (6): 643-50. 10.1111/j.1432-2277.2005.00134.x.CrossRefPubMed
14.
go back to reference Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L, et al: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 60 (2): 183-9. 1995 Jan 17 Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L, et al: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 60 (2): 183-9. 1995 Jan 17
Metadata
Title
Posttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case report
Authors
Roland Schmitt
Ute Kettritz
Friedrich C Luft
Ralph Kettritz
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2006
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-7-9

Other articles of this Issue 1/2006

BMC Nephrology 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.